- Patients are being overtreated with cancer drugs, as evidence suggests lower doses are often just as effective with fewer side effects.
- A study estimated $31 billion could have been saved in 2024 alone through dose optimization, but financial incentives for drugmakers and hospitals block this research.
- The FDA’s “Project Optimus” promotes lower-dose studies, but the agency lacks legal power to force drugmakers to test reduced dosages post-approval.
- Fewer than half of cancer drugs approved since 2000 have proven to extend survival, while the median price has quadrupled to $25,000 per month.
- Patient advocates demand informed consent, arguing people deserve plain facts about a drug’s true benefits and costs before risking their savings and health.
(Natural News)—Why are cancer patients being prescribed FDA-approved doses that may be far higher than necessary? A recent investigation by KFF Health News highlights a growing movement of researchers and doctors challenging standard dosing protocols for expensive immunotherapies and other cancer drugs. Their work suggests many patients could receive lower or less frequent doses, reducing side effects and saving billions in healthcare costs without compromising outcomes. Oncologists worldwide are finding that less can be more, raising questions about the financial incentives baked into current prescribing practices.
A patient’s gamble prompts a wider look at dosing
Economist Chuck Manski’s decision to stop his immunotherapy treatment early, due to severe side effects, is a case in point. After six months of nivolumab (Opdivo) for advanced melanoma in 2022, Manski faced a year-long FDA-recommended protocol. His oncologist could not explain why a full year was optimal, leading Manski to research the issue himself and ultimately stop treatment. He showed no signs of cancer at the time.
Manski’s experience is echoed by doctors elsewhere. In India, oncologists report using as little as one-twelfth of the labeled nivolumab dose with powerful results against several cancers. Clinical trials in Europe are also testing whether a 50% reduction in standard nivolumab doses can be just as effective for lung cancer patients.
Profit motive cited as a barrier to lower-dose research
Critics argue the primary obstacle to dose-optimization studies is financial. Drug companies earn more revenue from higher doses, and providers benefit too. A federal program lets hospitals buy drugs at a discount while charging insurers more, and doctors receive a percentage of the drug’s price for each infusion.
One study estimated that using minimum necessary dosages for 29 expensive cancer drugs could have saved the U.S. healthcare system roughly $31 billion in 2024 alone. That financial reality discourages research into lower doses once a drug reaches the market. One breast cancer researcher says she often starts patients on lower doses of Kisqali to avoid severe side effects — but insurers routinely challenge those prescriptions, likely because rebates are tied to the standard dosage.
Merck defends its dosing for pembrolizumab (Keytruda), saying it’s based on extensive testing and that unstudied changes could compromise effectiveness. A University of Chicago oncologist counters that the profitability of such drugs for hospitals is precisely why no one is rushing to test lower amounts.
FDA’s push for better dosing faces limits
The FDA has acknowledged the issue, launching “Project Optimus” in 2021 to encourage more precise dosing studies before approval. Health and Human Services says the agency has since approved lower, less toxic doses for four lung cancer drugs. But by law, the agency generally has no power to force drugmakers to study lower dosages once a drug is already approved and on the market.
Trials are now underway comparing standard nivolumab against lower doses, and testing whether breast cancer patients can start on reduced doses of Kisqali and Ibrance. For patients like Allegra Warfield, who suffered severe side effects and faced prohibitive costs, the lack of clear guidance has been a serious problem; she was left researching her own treatment online.
Patients say they deserve the full picture
A Bloomberg analysis found that fewer than half of cancer drugs approved since 2000 have been shown to extend survival, while the median price of new cancer drugs has quadrupled to roughly $25,000 a month — partly because the FDA allows approval based on preliminary tumor-shrinkage data rather than proof that patients live longer. Ibrance, approved in 2015, has generated over $40 billion in sales despite a 2022 study finding no statistically meaningful survival benefit for its main use — a detail buried deep in the drug’s label.
Patient advocates argue this is ultimately a question of informed consent: people facing cancer deserve to know, in plain terms, what a drug will and won’t do for them before they commit to a regimen that could cost them their savings and their health — regardless of whether that information helps the bottom line.
Sources for this article include:
Two Storms, One Harvest
Every food crisis in living memory has been a one-shock event. The 2008 price spike was a commodity bubble. The 2020 shortages were a logistics failure. The 2022 grain scare was a war on one exporter’s ports. Each time, the system bent, adjusted, and recovered, and each time the experts assured us afterward that global markets are simply too big and too diversified to fail.
What nobody in Washington seems eager to discuss is that 2026 is shaping up to be something the modern food system has never actually faced. Two independent shocks, one climatic and one geopolitical, are converging on the same harvest cycle at the same time. Not sequentially. Simultaneously.
Start with the weather. The Pacific Ocean is currently building toward what forecasters now openly call a record event. NOAA’s Climate Prediction Center puts the odds of at least a strong El Niño near 88 percent, with roughly two in three odds it reaches “very strong” status, the tier reserved for perhaps three or four events in the entire satellite era. Every major global model now projects a median peak in Super El Niño territory, and most of them project it exceeding the 2015-16 event, which until now held the modern record. Sea surface anomalies were already brushing the super threshold in mid-July, months before these events normally peak. The atmosphere has already shifted into El Niño mode, and the event is forecast to crest in late fall and early winter.
This is not about “climate change.” It’s about the standard cycles of weather, and the cycle we’re currently in is one that has likely devastated societies in the past. We’re better prepared as a society today, but not all Americans are equally prepared.
Serious households have started doing the quiet math on their own. Grocery bills tell part of the story, and the forecast maps tell the rest, which is why long-term food storage has moved from fringe hobby to mainstream line item in the family budget, with established suppliers like Heaven’s Harvest seeing demand from people who five years ago would have rolled their eyes at the idea. That instinct is not paranoia. It is pattern recognition, and the pattern is worth walking through carefully.
Editor’s Note: Heaven’s Harvest IS a sponsor, but the warnings of this article are real and would be written even if we didn’t have a survival food sponsor. With that said, those who take advantage of what they offer can use promo code “Patriot” for 15% off.
The Fertilizer Clock Is Already Running
While the Pacific warms, the second shock has been unfolding in the Strait of Hormuz. The conflict with Iran turned the world’s most important energy chokepoint into a contested waterway, and the consequences reach far beyond the gas pump. Roughly a third of global fertilizer trade moves through Hormuz, and the disruption sent urea prices up 86 percent year over year by March, with a 53 percent jump in a single month.
The World Bank projects energy prices rising about 24 percent in 2026 and fertilizer about 31 percent. By its own accounting, fertilizer prices ran 35 percent higher in the first five months of this year than the same period last year.
Here is the mechanism the nightly news will not explain. Fertilizer is not a grocery item. It is a time-delayed input. The nitrogen a farmer in Iowa or Punjab could not afford to apply this spring does not show up as a problem this spring. It shows up as a thinner harvest six to twelve months later.
The World Bank’s own food security brief concedes that the effects of reduced applications earlier this season “are likely to become visible only later in harvest outcomes.” Translate that from institutional language into plain English and it means this. The damage is already done, it is already in the ground, and we are simply waiting for it to arrive on the shelf.
Now check the calendar. Six to twelve months from the spring planting season lands us squarely in late 2026 and early 2027. Which is precisely when the strongest El Niño in the instrumental record is forecast to peak, bringing its signature droughts to Southeast Asia, Australia, southern Africa, northern Brazil, and South Asia, the very regions that grow the world’s rice, sugar, and oilseeds.
The World Bank warns openly that a strong El Niño “could disrupt multiple crop belts simultaneously” on top of the conflict-driven input costs. Their baseline projection assumes the Middle East disruptions ease by autumn. What in the last two years of Middle East history suggests that assumption is safe?
The System Has No Slack Left
The comfortable answer is that global markets always adjust. But adjustment requires slack, and the slack is gone. Global cereal production is expected to decline from last year’s records even before El Niño does its work. The UN World Food Programme, hardly a den of right-wing preppers, is calling this the most significant disruption to its supply chains since Covid and the invasion of Ukraine, and its supply chain director put the stakes bluntly.
Today’s supply chain challenges are tomorrow’s hunger crisis.
There is also a political dimension that markets cannot price. When food gets scarce, governments do not behave like economists. They behave like politicians. Export bans, hoarding mandates, and panic buying at the national level turned the modest rice shortfall of 2008 into a global crisis, and analysts are already warning that import-dependent nations are the first dominoes.
The 2015-16 Super El Niño, a far weaker event than what is now forecast, threw tens of millions into food stress across Africa and Asia. This one is projected to be stronger, and it arrives with fertilizer already rationed by price and shipping lanes already contested by missiles.
What Joseph Knew
Scripture does not treat preparation for lean years as faithlessness. It treats it as wisdom delivered in advance to those willing to act on it.
Behold, there come seven years of great plenty throughout all the land of Egypt: And there shall arise after them seven years of famine; and all the plenty shall be forgotten in the land of Egypt.
Joseph did not respond to that warning with a hashtag or a committee. He stored grain during the years of abundance, and when the famine came, Egypt stood while its neighbors begged. The lesson is not that famine is certain. It is that the time to prepare is precisely when preparation still looks optional.
Nobody who filled a pantry in a year of plenty has ever regretted it, and nobody standing in an empty aisle has ever been glad he waited for certainty.
None of this calls for panic, and panic is the enemy of sound judgment anyway. It calls for the same unglamorous prudence our grandparents considered ordinary. Keep some cash margin, know your local growers, and put real food in deep storage while it is cheap and available, because the entire arc of this story is that cheap and available is a closing window.
Families looking for a straightforward place to start can visit Heaven’s Harvest and use promo code Patriot for 15 percent off long-term storable food. The forecasts may yet soften, the strait may yet reopen, and we should pray they do. But hope is a fine thing to hold and a foolish thing to eat.
